新诊断多发性骨髓瘤持续MRD阴性及达雷妥尤单抗的影响:MAIA与ALCYONE研究
在不适合移植的新诊断多发性骨髓瘤患者中,MAIA和ALCYONE研究显示达雷妥尤单抗联合方案分别降低疾病进展或死亡风险44%和58%。MRD阴性及持续≥6或≥12个月与无进展生存期改善相关,且达雷妥尤单抗治疗提高了持续MRD阴性率。
要点
- 达雷妥尤单抗联合方案提高持续MRD阴性率,且转化为PFS改善。
- MRD阴性及持续≥6或≥12个月与PFS改善相关,不受治疗组影响。
- MAIA和ALCYONE中位随访分别为36.4和40.1个月。
核心结论
- 达到MRD阴性或持续MRD阴性的新诊断多发性骨髓瘤患者获得深度缓解和临床结局改善。
研究设计与样本
- MAIA研究:不适合移植的新诊断多发性骨髓瘤患者,D-Rd组n=368,Rd组n=369。
- ALCYONE研究:不适合移植的新诊断多发性骨髓瘤患者,D-VMP组n=350,VMP组n=356。
- MRD采用下一代测序(10-5)评估,于达到完全缓解或更好后及首次给药后12、18、24、30个月进行。
主要发现
- MAIA中位随访36.4个月,ALCYONE中位随访40.1个月。
- 达雷妥尤单抗组持续≥6个月MRD阴性率:D-Rd 14.9% vs Rd 4.3%;D-VMP 15.7% vs VMP 4.5%。
- 达雷妥尤单抗组持续≥12个月MRD阴性率:D-Rd 10.9% vs Rd 2.4%;D-VMP 14.0% vs VMP 2.8%。
- MRD阴性状态及持续≥6或≥12个月MRD阴性均与PFS改善相关,无论治疗组。
- 汇总分析中,MRD阴性患者较MRD阳性患者PFS改善。
关键数值与推荐
- MRD阴性定义为下一代测序检测灵敏度10-5。
- 持续MRD阴性定义为维持≥6或≥12个月。
临床怎么用
- 达雷妥尤单抗联合方案可提高持续MRD阴性率,支持其在不适合移植新诊断多发性骨髓瘤中的应用。
- MRD阴性及持续MRD阴性可作为预后指标,与PFS改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE. MRD assessments using next-generation sequencing (10-5) occurred for patients achieving complete response (CR) or better and after at least CR at 12, 18, 24, and 30 months from the first dose. Progression-free survival (PFS) by MRD status and sustained MRD negativity lasting ≥6 and ≥12 months were analyzed in the intent-to-treat population and among patients achieving at least CR. In MAIA (D-Rd, n = 368; lenalidomide and dexamethasone [Rd], n = 369) and ALCYONE (D-VMP, n = 350; bortezomib/melphalan/prednisone [VMP], n = 356), the median duration of follow-up was 36.4 and 40.1 months, respectively. MRD-negative status and sustained MRD negativity lasting ≥6 and ≥12 months were associated with improved PFS, regardless of treatment group. However, daratumumab-based therapy improved rates of MRD negativity lasting ≥6 months (D-Rd, 14.9% vs Rd, 4.3%; D-VMP, 15.7% vs VMP, 4.5%) and ≥12 months (D-Rd, 10.9% vs Rd, 2.4%; D-VMP, 14.0% vs VMP, 2.8%), both of which translated to improved PFS vs control groups. In a pooled analysis, patients who were MRD negative had improved PFS vs patients who were MRD positive. Patients with NDMM who achieved MRD-negative status or sustained MRD negativity had deep remission and improved clinical outcomes. These trials were registered at www.clinicaltrials.gov as #NCT02252172 (MAIA) and #NCT02195479 (ALCYONE).
引用
- San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022. PMID: 34269818. doi:10.1182/blood.2020010439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。